Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like
tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML) …

There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3
(FLT3) tyrosine kinase inhibitors (TKI) in patients with acute myeloid leukemia (AML) …

Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with
FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance …

More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant
mutations in Fms-like tyrosine kinase 3 (FLT3). Among them, the internal tandem duplication …

Abstract Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells
of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target …

FMS-like tyrosine kinase 3 (FLT3) mutations occur in almost 30% of acute myeloid leukemia
(AML) patients. Despite the initial clinical efficacy of FLT3 inhibitors, many treated AML …

Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the
pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML). G-749 is a …

FMS-like tyrosine kinase 3 (FLT3) is classified as a type III receptor tyrosine kinase, which
exerts a key role in regulation of normal hematopoiesis. FLT3 mutation is the most common …

Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of blood cells. Although
significant progress has been made in treating many types of cancers during recent years …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …